ArticleFrontiers in public health2026
Data generation and modeling during COVID-19: utility, barriers, and priorities for future investments in public health response.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the COVID-19 pandemic, policymakers and business leaders had to rapidly make consequential decisions, and researchers rushed to provide useful information, making use of data, infectious disease models, and public health knowledge. Our study surveyed 112 individuals engaged in COVID-19 response in the US, including data collectors, modelers, and users of these tools to determine how useful different data-driven tools were for informing response work, the most impactful challenges, and the most promising opportunities for future investment. Respondents overwhelmingly found data, models, and collaborations with researchers to be useful. The most impactful challenges, and also the most promising areas for future investment, were in data availability and quality. Respondents wanted higher quality data, more granular data, and access to a variety of data types. The second most influential challenge was insufficient human resources, with public health institutions being particularly under-resourced. Academics also played a valuable role, despite incentives that often conflict with real-time response work. Our survey results also highlight the importance and challenges of translational work, including shortcomings in science communication and difficulty navigating political influences. This study provides concrete evidence of the value of data and modeling tools for epidemic response and outlines priorities for future investment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.